Investor Relations

Corporate Profile

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. 
 
Urovant recently reported positive long-term data for its lead product candidate, vibegron, an oral, once-daily small molecule beta-3 agonist being evaluated for overactive bladder (OAB). The extension of the 12-week pivotal phase 3 EMPOWUR study demonstrated a favorable long-term safety and tolerability profile for vibegron and further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period. 
 
Vibegron is also being evaluated in a phase 3 study for the treatment of OAB in men with benign prostatic hyperplasia and in a phase 2a study for abdominal pain associated with irritable bowel syndrome. 
 
Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy and Urovant Sciences intends to develop novel treatments for additional urologic diseases.

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
February 13, 2020
Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 13, 2020-- Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019 . Recent Business Highlights Submitted a New Drug Application for vibegron for the treatment of patients
Additional Formats